-
公开(公告)号:WO2021251337A1
公开(公告)日:2021-12-16
申请号:PCT/JP2021/021564
申请日:2021-06-07
Applicant: 公立大学法人富山県立大学 , テイカ製薬株式会社 , 国立研究開発法人産業技術総合研究所
IPC: A61P1/02 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/04 , A61P3/10 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/12 , A61P19/02 , A61P21/00 , A61P21/04 , A61P25/00 , A61P29/00 , A61P31/04 , A61P31/18 , A61P37/02 , A61P37/06 , A61P43/00 , C07C43/178 , C07C215/30 , C07D211/38 , A61P17/00 , A61P17/06 , C07D295/096 , C07D295/185 , C07D205/04 , C07D307/94 , A61K31/045 , A61K31/08 , A61K31/085 , A61K31/135 , A61K31/18 , A61K31/192 , A61K31/216 , A61K31/365 , A61K31/397 , A61K31/40 , A61K31/451 , A61K31/495 , A61K31/5375
Abstract: CB-7は、正常マウスにおけるTLR7阻害効果が弱かった。本発明は、CB-7よりもTLR7阻害効果が高い新規な化合物、その薬理学的に許容される塩、又はこれらのプロドラッグを提供する。また、本発明は、上記TLR7活性化阻害剤を含有する、TLR7の活性化を伴う疾患の予防又は治療薬も提供する。
-
公开(公告)号:WO2021250079A1
公开(公告)日:2021-12-16
申请号:PCT/EP2021/065428
申请日:2021-06-09
Applicant: GENETHON , UNIVERSITE D'EVRY VAL D'ESSONNE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Inventor: RICHARD, Isabelle , BIQUAND, Ariane
IPC: C12N15/113 , A61K31/713 , A61P9/10 , C12N2310/14 , C12N2310/531
Abstract: The present disclosure relates to the treatment of dilated cardiomyopathies, in particular to 5 the use of an inhibitor of CILP-1.
-
93.
公开(公告)号:WO2021245427A1
公开(公告)日:2021-12-09
申请号:PCT/GB2021/051397
申请日:2021-06-04
Applicant: PATHIOS THERAPEUTICS LIMITED
Inventor: MCCARTHY, Tom , MILNE, Gavin , MOECHEL, Tobias , NAYLOR, Alan , MILLER, David
IPC: A61P9/10 , A61P11/06 , A61P35/00 , A61P37/02 , C07D451/00 , C07D471/08 , C07D487/04 , A61K31/46
Abstract: One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring A is a 5 or 6 membered aromatic or heteroaromatic ring, wherein said aromatic or heteroaromatic ring is optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, alkoxy, NR11R11',OH, alkyl, haloalkyl, aralkyl, aryl, and heteroaryl, and wherein said aryl and heteroaryl substituents are in turn optionally substituted with one or more substituents each independently selected from F, Cl, Br, I, CN, alkoxy, NR11R11' OH, alkyl, haloalkyl, and aralkyl; Y is selected from C=N-OH and CR10R10' wherein R10 and R10' are each independently selected from H, F, alkyl, and haloalkyl; R1, R4, and R5 are each independently selected from H, F, Cl, Br, and I; R2 and R3 are each independently selected from H, F, Cl, Br, I, CN, methoxy, and haloalkyl; and R11 and R11' are each independently selected from H, alkyl, haloalkyl, COR12, and SO2R13, wherein R12 and R13 are both alkyl; for use as a medicament. Further aspects of the invention relate to compounds of formula (I) for use in the field of immuno-oncology, immunology, and related applications, and compounds of formula (I) per se.
-
公开(公告)号:WO2021241966A1
公开(公告)日:2021-12-02
申请号:PCT/KR2021/006448
申请日:2021-05-24
Applicant: 한국세라믹기술원
IPC: A61K47/69 , A61K33/26 , A61P39/06 , A61P9/10 , A61P25/28 , A61P17/02 , A61K8/19 , A61K8/84 , A61Q19/00 , A61Q19/08
Abstract: 본 발명은 활성산소 제거를 위한 프러시안 블루/플루로닉 나노입자 복합체 및 이의 용도에 관한 것이다. 본 발명에 따른 프러시안 블루/플루로닉 나노입자 복합체는 활성산소제거 능력 및 상처 치유 능력이 뛰어나고 안정적이며 생체적합성이 우수하므로, 약제학적 조성물, 의약외품 조성물, 화장료 조성물, 식품 조성물, 활성산소 제거 용도, 활성산소 과잉생성으로 인해 유발되는 질환 또는 증상의 예방, 개선 또는 치료 방법의 개발에 효과적으로 사용될 수 있다.
-
公开(公告)号:WO2021239863A1
公开(公告)日:2021-12-02
申请号:PCT/EP2021/064166
申请日:2021-05-27
Applicant: MISSION THERAPEUTICS LIMITED
IPC: C07D413/12 , A61K31/422 , A61K31/4245 , A61K31/4025 , A61P35/00 , A61P25/00 , A61P25/28 , A61P3/00 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00
Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: Formula (I), Formula (II)..
-
公开(公告)号:WO2021227597A1
公开(公告)日:2021-11-18
申请号:PCT/CN2021/077638
申请日:2021-02-24
Applicant: 广东省科学院动物研究所
IPC: A61K36/068 , A61P9/10
Abstract: 冬虫夏草提取物在制备促血管新生药物和/或治疗缺血性心脑血管疾病药物中的应用。该冬虫夏草提取物以冬虫夏草为原料,依次用乙酸乙酯、乙醇水溶液和水提取,分别得到提取物后,将其混匀后干燥,即得。
-
公开(公告)号:WO2021226677A1
公开(公告)日:2021-11-18
申请号:PCT/AU2021/050454
申请日:2021-05-14
Applicant: THE HEART RESEARCH INSTITUTE LTD , THE UNIVERSITY OF SYDNEY
Inventor: JACKSON, Shaun , SCHOENWAELDER, Simone
IPC: A61K31/5377 , A61K31/4709 , A61K38/04 , A61K38/49 , A61K38/58 , A61P7/02 , A61P9/10
Abstract: The present disclosure relates to the use of anti-platelet agents for the treatment of thrombosis and related conditions in a subject. The anti-platelet agent, preferably a phosphoinositide 3-kinase beta (ΡΙ3Κβ) inhibitor such as TGX221 or AZD6482, may be administered alone or in combination with a thrombolytic agent, preferably recombinant tissue plasminogen activator (rtPA), and/or an anticoagulant agent, preferably argatroban.
-
公开(公告)号:WO2021226479A1
公开(公告)日:2021-11-11
申请号:PCT/US2021/031327
申请日:2021-05-07
Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , VETERANS AFFAIRS MEDICAL CENTER , BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , INVIXA, INC.
Inventor: ZEKI, Amir A. , KRISHNAN, Ramaswamy , GHOSH, Chandra C.
IPC: A61P9/10 , A61K31/57 , G01N33/68 , A61K31/427
Abstract: The present disclosure relates to methods and formulations for treating respiratory viral infections by administering a statin by inhalation.
-
公开(公告)号:WO2021226310A2
公开(公告)日:2021-11-11
申请号:PCT/US2021/031032
申请日:2021-05-06
Applicant: OHIO STATE INNOVATION FOUNDATION
Inventor: VEERARAGHAVAN, Rengasayee , MEZACHE, Louisa
IPC: A61P9/10 , A61P9/06 , A61P39/06 , A61K38/1709 , C07K14/435
Abstract: Disclosed herein is a method for treating atrial fibrillation (AF) or reentrant ventricular arrhythmias in a subject that involves administering to the subject a therapeutically effective amount of a gap junction or pannexin channel inhibitor in an amount effective to preserve barrier function. In some embodiments, the subject has paroxysmal AF.
-
公开(公告)号:WO2021224942A1
公开(公告)日:2021-11-11
申请号:PCT/IN2021/050433
申请日:2021-05-04
Applicant: ALKEM LABORATORIES LTD.
Inventor: LEVIN, Daniel , PARIHAR, Jayprakash , PAWAR, Prashant , CHAUDHARI, Pramod , MANDAVIYA, Jamankumar , SHEJUL, Dattatray , RAY, Sitasharan
IPC: C07D211/90 , A61K31/44 , A61P9/10
Abstract: The present invention relates to the polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof. Particularly, the present invention relates to crystalline hydrate and crystalline anhydrous forms of Amlodipine benzoate. The present invention also relates to the processes for the preparation of polymorphic forms of the present invention. Further, the present invention relates to a process for the preparation of Amlodipine benzoate.
-
-
-
-
-
-
-
-
-